Seglentis Approved to Manage Acute Pain
October 18, 2021HIV Treatment Biktarvy Approved to Treat Younger Children
October 18, 2021October 18, 2021 – TyrvayaTM (varenicline solution – Oyster Pharma) nasal spray 0.03mg has received U.S. FDA approval to treat the signs and symptoms of dry eye disease.
- It is the first and only FDA-approved nasal spray for dry eye disease treatment.
- The recommended dosing is one spray in each nostril twice daily, approximately 12 hours apart. Before initial use, the spray must be primed with seven actuations. It must be reprimed with one spray if not used for more than five days after initial priming.
- Tyrvaya has launched at a wholesale acquisition cost (WAC) of $296.14 per bottle.